A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.
Sponsor: Sairam Parthasarathy
You may qualify if…
- ✓ Obstructive sleep apnea (AHI \>/= 5 per hour), diagnosed in the past 6 months
- ✓ Two or more of the following symptoms: snoring, fragmented sleep, witnessed apneas, or daytime sleepiness
- ✓ Willingness/ability to use any of the 3 treatments for OSA (PAP, dental device, or atomoxetine-oxybutynin)
- ✓ Health insurance of any type
You may not qualify if…
- ✕ Prior treatment for OSA in past year
- ✕ Central sleep apnea or narcolepsy
- ✕ Contraindication for dental device (temporomandibular joint problems, severe periodontal disease, insufficient dentition)
- ✕ Heart failure with reduced ejection fraction of \</= 45%
- ✕ Active coronary artery disease (angina or infarction within 3 months of enrollment)
- ✕ Current untreated depression
- ✕ Untreated narrow angle glaucoma
- ✕ Untreated hypothyroidism
Where it's recruiting
Source: ClinicalTrials.gov · NCT07679282 · last updated 2026-09-11